Core Viewpoint - Lepu Biopharma-B (02157) experienced a 6.16% increase in stock price, reaching 10.17 CNY per share with a trading volume of 200 million CNY as of August 22 [1] Company Overview - Lepu Biopharma focuses on biopharmaceutical research and development in the oncology treatment sector, particularly in targeted therapy and immunotherapy innovations [1] - The company possesses end-to-end capabilities in drug discovery, clinical development, CMC, and GMP-compliant production [1] - Lepu Biopharma has established a professional sales and marketing team to meet clinical needs and provide optimized and innovative drug solutions [1] Financial Performance - As of the mid-year report for 2025, Lepu Biopharma reported total revenue of 466 million CNY and a net profit of 41.75 million CNY [1] - The company's net profit attributable to shareholders for the fiscal year 2025 increased by 121.69% year-on-year, with basic earnings per share of 0.02 CNY [1]
乐普生物-B(02157)上涨6.16%，报10.17元/股